GO
Loading...

Bull Case for Drug Stocks

Wednesday, 4 Jan 2012 | 12:20 PM ET

Barbara Ryan, analyst at Deutsche Bank, explains why she has a "buy" rating on Bristol Myers Squibb, Pfizer and Merk with a $43 price target. "Bristol Myers is clearly the growth name in the group," she adds.